Introdução
Esta página fornece uma análise abrangente do histórico conhecido de negociações internas de Noubar Afeyan. Insiders são oficiais, diretores ou investidores significativos em uma empresa. É ilegal para insiders realizarem negociações em suas próprias empresas baseados em informações específicas, não públicas. Isso não significa que seja ilegal para eles realizarem qualquer negociação em suas próprias empresas. No entanto, eles devem reportar todas as negociações à SEC através de um Formulário 4. Apesar dessas restrições, pesquisas acadêmicas sugerem que insiders - em geral - tendem a superar o mercado em suas próprias empresas.
Rentabilidade Média de Negociação
A rentabilidade média de negociação é o retorno médio de todas as compras de mercado abertas feitas pelo insider nos últimos três anos. Para calcular isso, examinamos cada compra de mercado aberto, não planejada, feita pelo insider, excluindo todas as negociações que foram marcadas como parte de um plano de negociação 10b5-1. Em seguida, calculamos o desempenho médio dessas negociações ao longo de 3, 6 e 12 meses, fazendo a média de cada uma dessas durações para gerar uma métrica de desempenho final para cada negociação. Finalmente, fazemos a média de todas as métricas de desempenho para calcular uma métrica de desempenho para o insider. Esta lista inclui apenas insiders que fizeram pelo menos três negociações nos últimos dois anos.
Se a rentabilidade de negociação deste insider é "N/A", então o insider ou não fez quaisquer compras de mercado aberto nos últimos três anos, ou as negociações que eles fizeram são muito recentes para calcular uma métrica de desempenho confiável.
Frequência de Atualização: Diariamente
Empresas com Posições Internas Reportadas
As declarações à SEC indicam que Noubar Afeyan reportou posses ou negociações nas seguintes empresas:
Como Interpretar os Gráficos
Os gráficos a seguir mostram o desempenho das ações dos a ativos ubsequentes a cada transação de mercado aberto, não planejada feita por Noubar Afeyan. Transações não planejadas são negociações que não foram feitas como parte de um plano de negociação 10b5-1. O desempenho das ações é representado como mudança percentual cumulativa no preço das ações. Por exemplo, se uma transação interna foi feita em 1 de janeiro de 2019, o gráfico mostrará a mudança percentual diária da segurança até o dia presente. Se o preço da ação passasse de $10 para $15 durante este período, a mudança percentual cumulativa no preço das ações seria de 50%. Uma mudança no preço de $10 para $20 seria de 100%, e uma mudança no preço de $10 para $5 seria de -50%.
Ultimamente, estamos tentando determinar quão estreitamente as negociações do interno correlacionam-se a retornos excessivos (positivos ou negativos) no preço da ação para ver se o interno está cronometrando suas transações para lucrar com informações internas. Considere a situação onde um interno estava fazendo isso. Nesta situação, esperaríamos (a) retornos positivos após compras, ou (b) retornos negativos após vendas. No caso de (a), o gráfico de COMPRA mostraria uma série de curvas ascendentes, indicando retornos positivos após cada transação de compra. No caso de (b), o gráfico de VENDA mostraria uma série de curvas descendentes, indicando retornos negativos após cada transação de venda.
No entanto, isso sozinho não é suficiente para tirar conclusões. Se, por exemplo, o preço da ação da empresa estivesse em uma escalada não cíclica ao longo de muitos anos, então esperaríamos que todos os gráficos pós-compra tivessem uma inclinação ascendente. Da mesma forma, declínios não cíclicos ao longo de muitos anos resultariam em gráficos pós-negociação inclinados para baixo. Nenhum desses gráficos sugeriria atividade de negociação interna.
O indicador mais forte seria uma situação em que o preço da ação fosse extremamente cíclico, e houvesse sinais positivos no gráfico de COMPRA e gráficos negativos no gráfico de VENDA. Esta situação seria altamente sugestiva de um interno que estava cronometrando transações para sua vantagem financeira.
Compras Internas AGIO / Agios Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas AGIO / Agios Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas BGMD / BG Medicine, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas BGMD / BG Medicine, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas CARM / Carisma Therapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas CARM / Carisma Therapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas EDIT / Editas Medicine, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas EDIT / Editas Medicine, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas EVLO / Evelo Biosciences, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas EVLO / Evelo Biosciences, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas FHTX / Foghorn Therapeutics Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas FHTX / Foghorn Therapeutics Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas KLDO / Kaleido Biosciences, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas KLDO / Kaleido Biosciences, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas MCRB / Seres Therapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas MCRB / Seres Therapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas QTRX / Quanterix Corporation - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas QTRX / Quanterix Corporation - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas RNAC / Cartesian Therapeutics, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas RNAC / Cartesian Therapeutics, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas SANA / Sana Biotechnology, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas SANA / Sana Biotechnology, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas SYRS / Syros Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas SYRS / Syros Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Compras Internas TMDX / TransMedics Group, Inc. - Análise de Lucro de Curto Prazo
Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em AGIO / Agios Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Máx |
Preço em Máx |
Lucro Máx ($) |
Retorno Máx (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Vendas Internas TMDX / TransMedics Group, Inc. - Análise de Perda de Curto Prazo
Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em AGIO / Agios Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.
A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.
| Data de Negociação | Ticker | Insider | Ações Reportadas |
Preço Reportado |
Ações Ajustadas |
Preço Ajustado |
Base de Custos | Dias para Mín |
Preço em Mín |
Máxima Perda Evitada ($) |
Máxima Perda Evitada (%) |
|---|---|---|---|---|---|---|---|
| Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo |
O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.
Histórico de Negociações Insider
Esta tabela mostra a lista completa de negociações insider realizadas por Noubar Afeyan conforme divulgadas para a Comissão de Valores Mobiliários (SEC).
| Data do Arquivo | Data da Transação | Formulário | Ticker | Ativo | Código | Ações | Ações Restantes | Variação Percentual |
Preço da Ação |
Valor da Transação |
Valor Restante |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -9,263 | 3,924 | -70.24 | 46.84 | -433,879 | 183,800 | |
| 2026-05-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 9,263 | 13,187 | 236.06 | 19.15 | 177,386 | 252,531 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 1,562,500 | 16.00 | 25,000,000 | 25,000,000 | ||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 4,340,252 | 56.25 | 16.00 | 25,000,000 | 69,444,032 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 15,264,724 | 11.40 | 16.00 | 25,000,000 | 244,235,584 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2,777,752 | 2,777,752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2,777,752 | 2,777,752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 987,491 | 987,491 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 13,702,224 | 13,702,224 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 12,723,940 | 12,723,940 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 1,562,500 | 16.00 | 25,000,000 | 25,000,000 | ||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 4,340,252 | 56.25 | 16.00 | 25,000,000 | 69,444,032 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
P - Purchase | 1,562,500 | 15,264,724 | 11.40 | 16.00 | 25,000,000 | 244,235,584 | |
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2,777,752 | 2,777,752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 2,777,752 | 2,777,752 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 987,491 | 987,491 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 13,702,224 | 13,702,224 | |||||
| 2026-03-02 |
|
4 | GENB |
Generate Biomedicines, Inc.
Common Stock |
C - Conversion | 12,723,940 | 12,723,940 | |||||
| 2026-02-26 | 3 | GENB |
Generate Biomedicines, Inc.
Common Stock |
25,016,458 | ||||||||
| 2026-02-26 | 3 | GENB |
Generate Biomedicines, Inc.
Common Stock |
25,016,458 | ||||||||
| 2025-12-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23,853 | 3,924 | -85.87 | 29.48 | -703,306 | 115,699 | |
| 2025-12-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 23,853 | 27,777 | 607.87 | 10.90 | 259,998 | 302,769 | |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,309 | 2,224,015 | -0.06 | 121.62 | -159,204 | 270,491,154 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,428 | 2,225,324 | -0.15 | 120.88 | -414,377 | 268,997,610 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,664 | 2,228,752 | -0.25 | 119.84 | -678,754 | 267,085,839 |
| 2024-08-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,599 | 2,234,416 | -0.21 | 118.96 | -547,107 | 265,811,043 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,000 | 2,239,015 | -0.09 | 119.01 | -238,026 | 266,471,892 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,832 | 2,241,015 | -0.30 | 118.30 | -808,208 | 265,106,248 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,500 | 2,247,847 | -0.16 | 117.25 | -410,376 | 263,560,960 |
| 2024-07-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,668 | 2,251,347 | -0.12 | 116.33 | -310,362 | 261,893,568 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,254,015 | -0.03 | 124.61 | -87,230 | 280,882,501 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,699 | 2,254,715 | -0.30 | 123.82 | -829,478 | 279,181,517 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,261,414 | -0.13 | 122.86 | -356,298 | 277,840,490 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,100 | 2,264,314 | -0.09 | 121.57 | -255,297 | 275,272,427 |
| 2024-07-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,601 | 2,266,414 | -0.11 | 120.86 | -314,347 | 273,910,637 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2,269,015 | -0.02 | 119.95 | -59,976 | 272,172,887 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,269,515 | -0.05 | 119.28 | -131,211 | 270,714,331 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,000 | 2,270,615 | -0.13 | 117.83 | -353,483 | 267,541,116 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,279 | 2,273,615 | -0.19 | 117.18 | -501,418 | 266,424,934 |
| 2024-07-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,121 | 2,277,894 | -0.27 | 116.01 | -710,089 | 264,255,294 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,284,015 | 0.00 | 134.05 | -13,405 | 306,172,211 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,284,115 | -0.03 | 131.56 | -92,089 | 300,488,348 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,705 | 2,284,815 | -0.12 | 130.76 | -353,695 | 298,753,270 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,300 | 2,287,520 | -0.10 | 129.84 | -298,631 | 297,010,911 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,435 | 2,289,820 | -0.06 | 128.78 | -184,798 | 294,880,501 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,291,255 | -0.05 | 127.50 | -140,254 | 292,143,032 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,292,355 | -0.05 | 125.71 | -138,277 | 288,163,695 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 2,293,455 | -0.07 | 124.90 | -187,352 | 286,455,970 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,600 | 2,294,955 | -0.07 | 123.74 | -197,978 | 283,969,240 |
| 2024-06-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,460 | 2,296,555 | -0.11 | 122.69 | -301,814 | 281,761,347 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,299,015 | 0.00 | 136.92 | -13,692 | 314,781,134 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,299,115 | -0.01 | 135.02 | -27,003 | 310,415,012 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,840 | 2,299,315 | -0.30 | 134.09 | -917,197 | 308,322,506 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,160 | 2,306,155 | -0.27 | 133.26 | -820,887 | 307,320,291 |
| 2024-06-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,700 | 2,312,315 | -0.07 | 132.22 | -224,782 | 305,744,695 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,314,015 | -0.01 | 150.24 | -30,048 | 347,657,614 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,400 | 2,314,215 | -0.06 | 149.39 | -209,150 | 345,726,827 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,601 | 2,315,615 | -0.07 | 148.61 | -237,929 | 344,130,492 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,397 | 2,317,216 | -0.28 | 147.55 | -943,876 | 341,904,757 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,031 | 2,323,613 | -0.13 | 146.55 | -444,188 | 340,521,535 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,263 | 2,326,644 | -0.05 | 145.57 | -183,861 | 338,700,735 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -408 | 2,327,907 | -0.02 | 144.46 | -58,940 | 336,293,868 |
| 2024-06-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,328,315 | -0.03 | 142.97 | -100,079 | 332,878,264 |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1,232 | 1,528,557 | -0.08 | 149.40 | -184,065 | 228,372,224 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -6,420 | 7,930,725 | -0.08 | 149.40 | -959,172 | 1,184,880,452 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31,531 | 1,529,789 | -2.02 | 148.29 | -4,675,871 | 226,859,142 | |
| 2024-06-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -163,649 | 7,937,145 | -2.02 | 148.29 | -24,268,230 | 1,177,034,155 | |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,721 | 1,946,931 | -0.09 | 154.86 | -266,510 | 301,497,257 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1,948,652 | -0.02 | 153.71 | -61,484 | 299,527,299 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,437 | 1,949,052 | -0.12 | 152.90 | -372,606 | 298,001,085 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,902 | 1,951,489 | -0.20 | 151.76 | -592,172 | 296,160,312 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,840 | 1,955,391 | -0.15 | 151.07 | -429,033 | 295,396,812 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,958,231 | -0.02 | 149.35 | -44,805 | 292,461,800 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,800 | 1,958,531 | -0.09 | 148.57 | -267,428 | 290,980,909 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1,960,331 | -0.04 | 147.78 | -103,443 | 289,688,698 |
| 2024-06-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 1,961,031 | -0.05 | 145.91 | -131,323 | 286,142,662 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,177 | 1,961,931 | -0.16 | 148.06 | -470,379 | 290,478,599 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,229 | 1,965,108 | -0.11 | 146.82 | -327,261 | 288,516,567 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,581 | 1,967,337 | -0.28 | 146.02 | -814,937 | 287,270,155 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,400 | 1,972,918 | -0.12 | 144.99 | -347,966 | 286,045,095 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 1,975,318 | -0.08 | 143.94 | -215,913 | 284,331,224 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 1,976,818 | -0.06 | 142.82 | -157,102 | 282,329,147 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,013 | 1,977,918 | -0.15 | 141.72 | -427,017 | 280,320,429 |
| 2024-05-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,000 | 1,980,931 | -0.05 | 141.01 | -141,010 | 279,331,080 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -97 | 1,981,931 | 0.00 | 164.67 | -15,973 | 326,364,578 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -625 | 1,982,028 | -0.03 | 163.92 | -102,451 | 324,896,408 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,223 | 1,982,653 | -0.11 | 163.02 | -362,401 | 323,219,230 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,005 | 1,984,876 | -0.05 | 162.19 | -163,003 | 321,930,611 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -825 | 1,985,881 | -0.04 | 160.24 | -132,194 | 318,208,635 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,200 | 1,986,706 | -0.11 | 159.57 | -351,050 | 317,015,299 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,923 | 1,988,906 | -0.10 | 158.25 | -304,320 | 314,750,142 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,802 | 1,990,829 | -0.09 | 157.41 | -283,656 | 313,379,777 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1,992,631 | -0.03 | 155.66 | -93,396 | 310,172,941 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,993,231 | -0.01 | 153.84 | -30,768 | 306,638,657 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -800 | 1,993,431 | -0.04 | 152.92 | -122,336 | 304,835,469 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 1,994,231 | -0.04 | 151.73 | -106,213 | 302,590,453 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 1,994,931 | -0.02 | 150.60 | -60,238 | 300,426,634 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,995,331 | -0.02 | 149.45 | -44,836 | 298,208,803 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 1,995,631 | -0.03 | 148.21 | -88,924 | 295,765,885 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,996,231 | -0.02 | 147.06 | -44,119 | 293,572,318 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,996,531 | -0.01 | 145.03 | -14,503 | 289,556,891 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,996,631 | -0.01 | 144.40 | -28,879 | 288,303,533 |
| 2024-05-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,996,831 | -0.01 | 142.95 | -14,295 | 285,446,991 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 1,996,931 | -0.01 | 129.15 | -25,830 | 257,903,639 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,711 | 1,997,131 | -0.29 | 128.75 | -735,272 | 257,123,826 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,600 | 2,002,842 | -0.13 | 127.71 | -332,036 | 255,775,541 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,001 | 2,005,442 | -0.10 | 126.62 | -253,368 | 253,930,670 |
| 2024-05-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,488 | 2,007,443 | -0.22 | 125.53 | -563,357 | 251,984,483 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,996 | 2,011,931 | -0.40 | 122.07 | -976,063 | 245,594,204 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,004 | 2,019,927 | -0.25 | 121.59 | -608,416 | 245,594,844 |
| 2024-05-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,000 | 2,024,931 | -0.10 | 120.37 | -240,741 | 243,741,957 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -700 | 2,026,931 | -0.03 | 113.40 | -79,379 | 229,851,138 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,500 | 2,027,631 | -0.07 | 112.77 | -169,151 | 228,650,473 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,246 | 2,029,131 | -0.21 | 111.55 | -473,650 | 226,353,621 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,572 | 2,033,377 | -0.22 | 110.42 | -504,860 | 224,534,232 |
| 2024-05-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,982 | 2,037,949 | -0.20 | 109.70 | -436,815 | 223,557,707 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,041,931 | -0.05 | 109.91 | -120,901 | 224,428,636 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,153 | 2,043,031 | -0.20 | 109.04 | -452,847 | 222,774,143 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,821 | 2,047,184 | -0.28 | 108.30 | -630,388 | 221,700,815 |
| 2024-04-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,926 | 2,053,005 | -0.19 | 107.16 | -420,700 | 219,994,473 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -282 | 2,056,931 | -0.01 | 104.49 | -29,466 | 214,927,897 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,475 | 2,057,213 | -0.31 | 103.69 | -671,398 | 213,314,062 |
| 2024-04-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,243 | 2,063,688 | -0.40 | 103.10 | -849,839 | 212,762,725 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -389 | 2,071,931 | -0.02 | 109.36 | -42,542 | 226,592,176 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -748 | 2,072,320 | -0.04 | 108.56 | -81,205 | 224,977,483 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,512 | 2,073,068 | -0.36 | 107.31 | -806,136 | 222,467,354 |
| 2024-04-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,351 | 2,080,580 | -0.30 | 106.59 | -676,982 | 221,778,385 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,086,931 | 0.00 | 104.15 | -10,415 | 217,353,864 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,702 | 2,087,031 | -0.13 | 103.64 | -280,044 | 216,306,363 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,500 | 2,089,733 | -0.17 | 102.64 | -359,252 | 214,497,091 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,832 | 2,093,233 | -0.18 | 101.33 | -388,289 | 212,103,113 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,167 | 2,097,065 | -0.15 | 100.66 | -318,775 | 211,080,497 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,499 | 2,100,232 | -0.07 | 99.40 | -149,000 | 208,762,221 |
| 2024-04-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,101,731 | -0.01 | 97.47 | -19,494 | 204,855,721 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,973 | 2,101,931 | -0.14 | 110.75 | -329,256 | 232,785,916 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,544 | 2,104,904 | -0.22 | 110.24 | -500,931 | 232,044,827 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,100 | 2,109,448 | -0.15 | 109.09 | -338,176 | 230,117,362 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,466 | 2,112,548 | -0.07 | 107.79 | -158,020 | 227,711,126 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,100 | 2,114,014 | -0.05 | 106.71 | -117,376 | 225,577,344 |
| 2024-03-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,817 | 2,115,114 | -0.09 | 105.73 | -192,106 | 223,624,446 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,778 | 2,116,931 | -0.27 | 103.18 | -596,147 | 218,414,991 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,109 | 2,122,709 | -0.33 | 102.15 | -726,159 | 216,827,083 |
| 2024-03-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,113 | 2,129,818 | -0.10 | 101.05 | -213,514 | 215,213,849 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,131,931 | -0.01 | 112.44 | -22,487 | 239,703,662 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,404 | 2,132,131 | -0.07 | 111.69 | -156,806 | 238,127,264 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,803 | 2,133,535 | -0.18 | 110.80 | -421,373 | 236,395,891 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -412 | 2,137,338 | -0.02 | 109.50 | -45,113 | 234,033,381 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2,137,750 | -0.03 | 108.52 | -65,109 | 231,977,941 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,300 | 2,138,350 | -0.11 | 107.66 | -247,617 | 230,213,692 |
| 2024-03-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,281 | 2,140,650 | -0.29 | 106.60 | -669,527 | 228,183,871 |
| 2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,100 | 2,146,931 | -0.38 | 76.17 | -616,966 | 163,528,729 |
| 2023-11-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,900 | 2,155,031 | -0.09 | 75.30 | -143,066 | 162,269,309 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2,156,931 | -0.02 | 78.42 | -31,366 | 169,135,744 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,100 | 2,157,331 | -0.14 | 77.34 | -239,754 | 166,847,764 |
| 2023-10-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,500 | 2,160,431 | -0.30 | 76.73 | -498,734 | 165,766,198 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,166,931 | 0.00 | 105.58 | -10,558 | 228,784,575 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -500 | 2,167,031 | -0.02 | 104.82 | -52,408 | 227,139,521 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,700 | 2,167,531 | -0.26 | 103.76 | -591,421 | 224,898,681 |
| 2023-10-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,700 | 2,173,231 | -0.40 | 102.88 | -895,054 | 223,581,571 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,866 | 2,181,931 | -0.18 | 104.04 | -402,206 | 227,001,119 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,604 | 2,185,797 | -0.26 | 103.22 | -578,445 | 225,618,185 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,700 | 2,191,401 | -0.12 | 102.03 | -275,486 | 223,592,369 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,800 | 2,194,101 | -0.08 | 100.94 | -181,690 | 221,470,141 |
| 2023-10-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,030 | 2,195,901 | -0.05 | 100.02 | -103,018 | 219,628,748 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,196,931 | -0.01 | 100.16 | -20,033 | 220,055,594 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,596 | 2,197,131 | -0.21 | 99.49 | -457,245 | 218,587,510 |
| 2023-09-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,204 | 2,201,727 | -0.24 | 98.46 | -512,367 | 216,774,114 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,006 | 2,206,931 | -0.05 | 105.77 | -106,404 | 233,424,885 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,380 | 2,207,937 | -0.42 | 105.06 | -985,422 | 231,956,146 |
| 2023-09-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,614 | 2,217,317 | -0.21 | 103.87 | -479,265 | 230,316,930 |
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -70,813 | 0 | -100.00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2,431,281 | 7,293,841 | -25.00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -1,181,745 | 0 | -100.00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -345,069 | 1,035,208 | -25.00 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -4,926,378 | 8,057,470 | -37.94 | ||||
| 2023-09-15 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
J - Other | -2,825,989 | 8,615,337 | -24.70 | ||||
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 2,221,931 | 0.00 | 114.32 | -11,432 | 254,011,152 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250 | 2,222,031 | -0.01 | 113.22 | -28,305 | 251,578,350 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2,222,281 | -0.04 | 112.17 | -100,957 | 249,283,038 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,895 | 2,223,181 | -0.17 | 111.23 | -433,243 | 247,285,757 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,400 | 2,227,076 | -0.06 | 110.26 | -154,363 | 245,555,841 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,174 | 2,228,476 | -0.19 | 108.77 | -453,992 | 242,383,981 |
| 2023-09-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,281 | 2,232,650 | -0.19 | 108.21 | -463,229 | 241,585,903 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 1,982,209 | -0.02 | 108.91 | -32,674 | 215,888,923 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,689 | 1,982,509 | -0.29 | 108.07 | -614,811 | 214,250,144 |
| 2023-09-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,011 | 1,988,198 | -0.45 | 107.27 | -966,608 | 213,273,602 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -100 | 1,997,209 | -0.01 | 117.21 | -11,721 | 234,092,867 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,336 | 1,997,309 | -0.22 | 116.57 | -505,463 | 232,833,500 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,717 | 2,001,645 | -0.24 | 115.43 | -544,460 | 231,040,074 |
| 2023-09-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,847 | 2,006,362 | -0.29 | 114.64 | -670,307 | 230,011,547 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,012,209 | -0.01 | 116.46 | -34,938 | 234,341,860 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,878 | 2,012,509 | -0.49 | 115.84 | -1,144,313 | 233,138,300 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,657 | 2,022,387 | -0.18 | 115.16 | -421,125 | 232,889,593 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -854 | 2,026,044 | -0.04 | 113.83 | -97,215 | 230,633,503 |
| 2023-08-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -311 | 2,026,898 | -0.02 | 112.61 | -35,022 | 228,252,227 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,027,209 | -0.01 | 99.50 | -29,850 | 201,707,296 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,000 | 2,027,509 | -0.20 | 98.82 | -395,289 | 200,362,900 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,200 | 2,031,509 | -0.06 | 98.07 | -117,679 | 199,221,555 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,032,709 | -0.14 | 96.44 | -279,672 | 196,031,813 |
| 2023-08-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,600 | 2,035,609 | -0.08 | 95.70 | -153,124 | 194,812,870 |
| 2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -113,960 | 0 | -100.00 | 14.92 | -1,700,283 | ||
| 2023-08-15 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
U - Other | -683,760 | 0 | -100.00 | 14.92 | -10,201,699 | ||
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -200 | 2,037,209 | -0.01 | 113.68 | -22,735 | 231,579,733 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -900 | 2,037,409 | -0.04 | 112.59 | -101,328 | 229,385,156 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,175 | 2,038,309 | -0.20 | 111.46 | -465,349 | 227,191,552 |
| 2023-08-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,725 | 2,042,484 | -0.47 | 110.59 | -1,075,464 | 225,873,404 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,101 | 2,052,209 | -0.05 | 121.29 | -133,544 | 248,920,023 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11,499 | 2,053,310 | -0.56 | 120.50 | -1,385,632 | 247,424,266 |
| 2023-07-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,400 | 2,064,809 | -0.12 | 119.61 | -287,053 | 246,962,306 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,149 | 2,067,209 | -0.25 | 126.08 | -649,185 | 260,633,504 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,004 | 2,072,358 | -0.43 | 125.26 | -1,127,819 | 259,578,589 |
| 2023-07-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -847 | 2,081,362 | -0.04 | 124.14 | -105,147 | 258,382,152 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,082,209 | -0.01 | 127.15 | -38,145 | 264,752,874 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,845 | 2,082,509 | -0.33 | 126.27 | -864,316 | 262,957,787 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,865 | 2,089,354 | -0.28 | 125.61 | -736,678 | 262,434,981 |
| 2023-07-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,990 | 2,095,219 | -0.09 | 124.59 | -247,942 | 261,051,926 |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 3,246,753 | 3,931,685 | 474.03 | 2.31 | 7,499,999 | 9,082,192 | |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,082,251 | 1,493,241 | 263.33 | 2.31 | 2,500,000 | 3,449,387 | |
| 2023-07-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,082,251 | 1,493,241 | 263.33 | 2.31 | 2,500,000 | 3,449,387 | |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -170 | 2,097,209 | -0.01 | 128.17 | -21,789 | 268,801,794 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,549 | 2,097,379 | -0.07 | 127.55 | -197,577 | 267,523,628 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,012 | 2,098,928 | -0.05 | 126.54 | -128,055 | 265,590,793 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,639 | 2,099,940 | -0.13 | 125.14 | -330,258 | 262,796,991 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,097 | 2,102,579 | -0.29 | 124.17 | -757,086 | 261,084,593 |
| 2023-07-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,533 | 2,108,676 | -0.17 | 123.46 | -436,169 | 260,327,861 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,096 | 2,112,209 | -0.10 | 122.82 | -257,441 | 259,432,070 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -8,073 | 2,114,305 | -0.38 | 121.87 | -983,873 | 257,674,790 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,131 | 2,122,378 | -0.15 | 120.77 | -378,123 | 256,314,073 |
| 2023-06-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,700 | 2,125,509 | -0.08 | 119.84 | -203,723 | 254,714,835 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -400 | 2,127,209 | -0.02 | 123.48 | -49,390 | 262,657,131 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,790 | 2,127,609 | -0.32 | 122.26 | -830,175 | 260,130,838 |
| 2023-06-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -7,810 | 2,134,399 | -0.36 | 121.60 | -949,662 | 259,533,527 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -530 | 2,142,209 | -0.02 | 128.15 | -67,918 | 274,516,371 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,002 | 2,142,739 | -0.14 | 127.19 | -381,823 | 272,533,902 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,997 | 2,145,741 | -0.28 | 126.17 | -756,658 | 270,734,150 |
| 2023-06-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,471 | 2,151,738 | -0.25 | 125.43 | -686,229 | 269,892,928 |
| 2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,702 | 2,157,209 | -0.13 | 126.59 | -342,054 | 273,087,343 |
| 2023-06-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -12,298 | 2,159,911 | -0.57 | 125.76 | -1,546,547 | 271,621,768 |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22,760 | 1,380,277 | -1.62 | 6.24 | -142,016 | 8,612,514 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -177,240 | 10,743,293 | -1.62 | 6.24 | -1,105,924 | 67,034,925 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -22,297 | 1,403,037 | -1.56 | 6.31 | -140,607 | 8,847,692 | |
| 2023-06-08 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -181,461 | 10,920,533 | -1.63 | 6.31 | -1,144,311 | 68,865,973 | |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -600 | 2,172,209 | -0.03 | 129.68 | -77,807 | 281,688,370 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,441 | 2,172,809 | -0.11 | 128.55 | -313,780 | 279,305,037 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -5,637 | 2,175,250 | -0.26 | 127.84 | -720,629 | 278,082,002 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,373 | 2,180,887 | -0.15 | 126.72 | -427,440 | 276,370,942 |
| 2023-06-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,949 | 2,184,260 | -0.13 | 125.69 | -370,666 | 274,544,226 |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -9,330 | 1,425,334 | -0.65 | 6.23 | -58,093 | 8,874,842 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -72,670 | 11,101,994 | -0.65 | 6.23 | -452,480 | 69,126,566 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -13,127 | 1,434,664 | -0.91 | 6.35 | -83,385 | 9,113,273 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -102,245 | 11,174,664 | -0.91 | 6.35 | -649,481 | 70,983,701 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -39,580 | 1,447,791 | -2.66 | 6.57 | -259,851 | 9,505,037 | |
| 2023-05-26 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
S - Sale | -308,290 | 11,276,909 | -2.66 | 6.57 | -2,023,986 | 74,035,163 | |
| 2023-03-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,187,209 | -0.46 | 139.00 | -1,390,000 | 304,022,051 |
| 2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1,329,324 | 1,329,324 | 5.78 | 7,683,493 | 7,683,493 | ||
| 2023-02-27 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 1,993,986 | 7,508,693 | 36.16 | 5.78 | 11,525,239 | 43,400,246 | |
| 2023-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,197,209 | -0.45 | 160.35 | -1,603,500 | 352,322,463 |
| 2023-02-17 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,207,209 | -0.45 | 173.17 | -1,731,700 | 382,222,383 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -11,000 | 2,217,209 | -0.49 | 169.32 | -1,862,516 | 375,416,941 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,100 | 2,228,209 | -0.09 | 168.27 | -353,364 | 374,937,609 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -300 | 2,230,309 | -0.01 | 166.59 | -49,977 | 371,547,176 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -3,700 | 2,230,609 | -0.17 | 165.83 | -613,577 | 369,905,459 |
| 2023-02-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -2,900 | 2,234,309 | -0.13 | 164.60 | -477,327 | 367,757,430 |
| 2023-01-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,237,209 | -0.44 | 194.33 | -1,943,300 | 434,756,825 |
| 2023-01-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,247,209 | -0.44 | 200.20 | -2,002,000 | 449,891,242 |
| 2023-01-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,257,209 | -0.44 | 188.57 | -1,885,700 | 425,641,901 |
| 2023-01-06 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,267,209 | -0.44 | 182.15 | -1,821,500 | 412,972,119 |
| 2022-12-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,277,209 | -0.44 | 201.70 | -2,017,000 | 459,313,055 |
| 2022-12-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,287,209 | -0.44 | 195.00 | -1,950,000 | 446,005,755 |
| 2022-12-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,297,209 | -0.43 | 172.16 | -1,721,600 | 395,487,501 |
| 2022-12-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,307,209 | -0.43 | 173.52 | -1,735,200 | 400,346,906 |
| 2022-11-25 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,317,209 | -0.43 | 178.01 | -1,780,100 | 412,486,374 |
| 2022-11-18 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,327,209 | -0.43 | 184.25 | -1,842,500 | 428,788,258 |
| 2022-11-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,337,209 | -0.43 | 162.50 | -1,625,000 | 379,796,462 |
| 2022-11-04 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,347,209 | -0.42 | 154.20 | -1,542,000 | 361,939,628 |
| 2022-10-28 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,357,209 | -0.42 | 137.25 | -1,372,500 | 323,526,935 |
| 2022-10-21 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,367,209 | -0.42 | 132.50 | -1,325,000 | 313,655,192 |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3,048,780 | 3,048,780 | 1.64 | 4,999,999 | 4,999,999 | ||
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 919,111 | 6,299,611 | 17.08 | 1.64 | 1,507,342 | 10,331,362 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 914,634 | 5,380,500 | 20.48 | 1.64 | 1,500,000 | 8,824,020 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2,757,333 | 14,101,638 | 24.31 | 1.64 | 4,522,026 | 23,126,686 | |
| 2022-10-17 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2,743,902 | 11,344,305 | 31.90 | 1.64 | 4,499,999 | 18,604,660 | |
| 2022-10-14 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,377,209 | -0.42 | 135.36 | -1,353,600 | 321,779,010 |
| 2022-10-07 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,387,209 | -0.42 | 122.40 | -1,224,000 | 292,194,382 |
| 2022-09-30 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,397,209 | -0.42 | 123.58 | -1,235,800 | 296,247,088 |
| 2022-09-23 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,407,209 | -0.41 | 130.37 | -1,303,700 | 313,827,837 |
| 2022-09-16 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,417,209 | -0.41 | 134.00 | -1,340,000 | 323,906,006 |
| 2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 210,743 | 1,188,920 | 21.54 | ||||
| 2022-09-16 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 722,590 | 1,865,767 | 63.21 | ||||
| 2022-09-09 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,427,209 | -0.41 | 129.68 | -1,296,800 | 314,760,463 |
| 2022-09-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,437,209 | -0.41 | 136.95 | -1,369,500 | 333,775,773 |
| 2022-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,447,209 | -0.41 | 165.24 | -1,652,400 | 404,376,815 |
| 2022-08-12 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,457,209 | -0.41 | 174.09 | -1,740,900 | 427,775,515 |
| 2022-08-05 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,467,209 | -0.40 | 167.99 | -1,679,900 | 414,466,440 |
| 2022-07-29 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,477,209 | -0.40 | 161.00 | -1,610,000 | 398,830,649 |
| 2022-07-22 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,487,209 | -0.40 | 167.00 | -1,670,000 | 415,363,903 |
| 2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,497,209 | -0.40 | 168.88 | -1,688,800 | 421,728,656 |
| 2022-07-15 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,497,209 | -0.40 | 168.88 | -1,688,800 | 421,728,656 |
| 2022-07-08 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,507,209 | -0.40 | 154.85 | -1,548,500 | 388,241,314 |
| 2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 5,825,495 | 5,825,495 | 3.15 | 18,350,309 | 18,350,309 | ||
| 2022-07-07 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 2,912,748 | 5,875,711 | 98.31 | 3.15 | 9,175,156 | 18,508,490 | |
| 2022-07-01 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,517,209 | -0.40 | 140.47 | -1,404,700 | 353,592,348 |
| 2022-06-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,527,209 | -0.39 | 127.69 | -1,276,900 | 322,699,317 |
| 2022-06-10 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,537,209 | -0.39 | 147.47 | -1,474,700 | 374,162,211 |
| 2022-06-03 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,547,209 | -0.39 | 146.31 | -1,463,100 | 372,682,149 |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 13,698,630 | 13,698,630 | 1.46 | 20,000,000 | 20,000,000 | ||
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 6,849,315 | 8,219,791 | 499.78 | 1.46 | 10,000,000 | 12,000,895 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,369,863 | 5,495,324 | 33.21 | 1.46 | 2,000,000 | 8,023,173 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,095,890 | 1,887,419 | 138.45 | 1.46 | 1,599,999 | 2,755,632 | |
| 2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 4,383,561 | 7,590,873 | 136.67 | 1.46 | 6,399,999 | 11,082,675 | |
| 2022-05-27 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,557,209 | -0.39 | 130.80 | -1,308,000 | 334,482,937 |
| 2022-05-20 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,567,209 | -0.39 | 138.38 | -1,383,800 | 355,250,381 |
| 2022-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -100 | 5,816,657 | 0.00 | 136.00 | -13,600 | 791,065,352 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -49,900 | 5,816,757 | -0.85 | 135.36 | -6,754,714 | 787,385,311 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -24,567 | 5,866,657 | -0.42 | 134.04 | -3,293,015 | 786,379,611 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -25,433 | 5,891,224 | -0.43 | 133.11 | -3,385,282 | 784,156,673 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -31,618 | 5,916,657 | -0.53 | 132.22 | -4,180,674 | 782,327,013 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -51,256 | 5,948,275 | -0.85 | 131.45 | -6,737,478 | 781,886,473 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -41,182 | 5,999,531 | -0.68 | 130.08 | -5,356,765 | 780,391,395 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -75,944 | 6,040,713 | -1.24 | 129.39 | -9,826,257 | 781,596,982 | |
| 2022-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -10,000 | 2,229,673 | -0.45 | 130.74 | -1,307,400 | 291,507,448 |
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
M - Exercise | -703 | 0 | -100.00 | ||||
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 5,415 | 5,415 | |||||
| 2022-05-02 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
M - Exercise | 703 | 2,239,673 | 0.03 | ||||
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,579,843 | 4,465,866 | 54.74 | 1.91 | 3,017,500 | 8,529,804 | |
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 947,905 | 2,004,657 | 89.70 | 1.91 | 1,810,499 | 3,828,895 | |
| 2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3,791,623 | 8,600,403 | 78.85 | 1.91 | 7,242,000 | 16,426,770 | |
| 2022-02-14 |
|
5 | MRNA |
Moderna, Inc.
Common Stock |
G - Gift | -100,000 | 2,238,970 | -4.28 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,666,666 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,666,667 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,333,333 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -13,333,333 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -666,667 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2,666,667 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3,000,000 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -27,388,000 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -22,275,232 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,112,000 | 0 | -100.00 | ||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 294,117 | 1,617,646 | 22.22 | 17.00 | 4,999,989 | 27,499,982 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1,323,529 | 1,323,529 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 661,764 | 5,514,707 | 13.64 | 17.00 | 11,249,988 | 93,750,019 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 4,852,943 | 4,852,943 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 970,588 | 970,588 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
P - Purchase | 220,588 | 8,617,413 | 2.63 | 17.00 | 3,749,996 | 146,496,021 | |
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 8,396,825 | 8,396,825 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 5,896,386 | 5,896,386 | |||||
| 2021-08-05 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
C - Conversion | 1,088,470 | 1,088,470 | |||||
| 2021-07-30 |
|
4 | OMGA |
Omega Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 19,852 | 19,852 | |||||
| 2021-07-29 | 3 | OMGA |
Omega Therapeutics, Inc.
Common Stock |
2,197,059 | ||||||||
| 2021-05-19 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -295,171 | 2,962,963 | -9.06 | ||||
| 2021-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Restricted Stock Units |
A - Award | 703 | 703 | |||||
| 2021-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 4,081 | 4,081 | |||||
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -4,888 | 9,116,657 | -0.05 | 121.07 | -591,810 | 1,103,790,130 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -1,000 | 9,121,545 | -0.01 | 123.44 | -123,440 | 1,125,963,515 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -31,943 | 9,122,545 | -0.35 | 123.08 | -3,931,538 | 1,122,801,014 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -14,379 | 9,154,488 | -0.16 | 121.71 | -1,750,038 | 1,114,173,510 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -225,732 | 9,168,867 | -2.40 | 120.76 | -27,259,283 | 1,107,227,794 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -344,542 | 9,394,599 | -3.54 | 119.81 | -41,278,061 | 1,125,525,570 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -611,922 | 9,739,141 | -5.91 | 118.90 | -72,758,505 | 1,157,999,448 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -883,277 | 10,351,063 | -7.86 | 118.04 | -104,265,815 | 1,221,883,986 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -558 | 11,234,340 | 0.00 | 131.30 | -73,265 | 1,475,068,842 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -6,610 | 11,234,898 | -0.06 | 130.56 | -862,994 | 1,466,814,801 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -83,242 | 11,241,508 | -0.74 | 129.54 | -10,783,377 | 1,456,253,050 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -123,374 | 11,324,750 | -1.08 | 128.74 | -15,883,527 | 1,457,981,157 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46,872 | 11,448,124 | -0.41 | 127.47 | -5,974,788 | 1,459,295,801 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -82,557 | 11,494,996 | -0.71 | 126.40 | -10,434,924 | 1,452,928,411 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -116,383 | 11,577,553 | -1.00 | 125.36 | -14,589,226 | 1,451,307,630 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -251,545 | 11,693,936 | -2.11 | 124.42 | -31,296,927 | 1,454,945,484 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -639,681 | 11,945,481 | -5.08 | 123.50 | -78,998,365 | 1,475,225,094 |
| 2021-03-31 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -284,300 | 12,585,162 | -2.21 | 122.53 | -34,836,672 | 1,542,121,567 |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 2,633,703 | 2.73 | 29.00 | 2,030,000 | 76,377,387 | |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 2,633,703 | 2.73 | 29.00 | 2,030,000 | 76,377,387 | |
| 2021-03-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 70,000 | 15,393,593 | 0.46 | 29.00 | 2,030,000 | 446,414,197 | |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -23,423 | 14,623,159 | -0.16 | 151.29 | -3,543,551 | 2,212,266,072 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -190,710 | 14,646,582 | -1.29 | 150.51 | -28,704,468 | 2,204,511,249 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -179,268 | 14,837,292 | -1.19 | 149.63 | -26,823,154 | 2,220,044,653 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -268,688 | 15,016,560 | -1.76 | 148.52 | -39,905,810 | 2,230,274,508 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -292,483 | 15,285,248 | -1.88 | 147.57 | -43,162,565 | 2,255,688,375 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -307,795 | 15,577,731 | -1.94 | 146.64 | -45,134,105 | 2,284,270,183 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -357,316 | 15,885,526 | -2.20 | 145.48 | -51,982,439 | 2,311,031,088 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -405,551 | 16,242,842 | -2.44 | 144.55 | -58,623,573 | 2,347,949,915 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -397,126 | 16,648,393 | -2.33 | 143.57 | -57,017,127 | 2,390,283,036 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -117,011 | 17,045,519 | -0.68 | 142.76 | -16,704,549 | 2,433,426,815 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -70,631 | 17,162,530 | -0.41 | 141.46 | -9,991,271 | 2,427,765,155 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -102,852 | 17,233,161 | -0.59 | 140.24 | -14,423,553 | 2,416,709,566 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -56,435 | 17,336,013 | -0.32 | 139.64 | -7,880,849 | 2,420,882,335 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -46,222 | 17,392,448 | -0.27 | 138.56 | -6,404,451 | 2,409,871,506 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122,142 | 17,438,670 | -0.70 | 137.29 | -16,768,948 | 2,394,165,468 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -9,985 | 17,560,812 | -0.06 | 136.48 | -1,362,773 | 2,396,734,743 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30,968 | 17,570,797 | -0.18 | 170.03 | -5,265,421 | 2,987,523,958 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54,274 | 17,601,735 | -0.31 | 169.14 | -9,179,910 | 2,977,159,218 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -58,377 | 17,656,009 | -0.33 | 168.11 | -9,813,857 | 2,968,181,688 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -122,715 | 17,714,386 | -0.69 | 167.10 | -20,505,750 | 2,960,084,529 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351,578 | 17,837,101 | -1.93 | 166.30 | -58,466,296 | 2,966,252,818 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -165,578 | 18,188,311 | -0.90 | 165.47 | -27,397,976 | 3,009,596,176 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -189,200 | 18,353,889 | -1.02 | 164.13 | -31,054,266 | 3,012,508,229 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -366,471 | 18,543,089 | -1.94 | 163.25 | -59,827,380 | 3,027,209,346 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -250,501 | 18,909,560 | -1.31 | 162.36 | -40,672,044 | 3,070,209,108 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -30,808 | 19,160,061 | -0.16 | 160.96 | -4,958,809 | 3,083,974,678 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -54,409 | 19,190,869 | -0.28 | 160.37 | -8,725,620 | 3,077,656,933 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -161,887 | 19,245,278 | -0.83 | 159.18 | -25,769,076 | 3,063,451,805 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -35,000 | 12,869,462 | -0.27 | 150.41 | -5,264,350 | 1,935,695,779 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -99,005 | 12,904,462 | -0.76 | 148.91 | -14,742,765 | 1,921,594,403 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -267,038 | 13,003,467 | -2.01 | 148.01 | -39,523,921 | 1,924,624,946 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -288,656 | 13,270,505 | -2.13 | 147.17 | -42,481,157 | 1,953,004,296 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -351,112 | 13,559,161 | -2.52 | 146.05 | -51,281,277 | 1,980,368,345 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -354,358 | 13,910,273 | -2.48 | 145.04 | -51,396,616 | 2,017,566,861 |
| 2021-02-24 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | X | -358,528 | 14,264,631 | -2.45 | 144.17 | -51,688,838 | 2,056,526,145 |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,667 | 738,333 | 10.75 | 11.50 | 824,170 | 8,490,830 | |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,667 | 738,333 | 10.75 | 11.50 | 824,170 | 8,490,830 | |
| 2021-02-10 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 71,666 | 1,685,444 | 4.44 | 11.50 | 824,159 | 19,382,606 | |
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11,585,199 | 0 | -100.00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -11,441,326 | 0 | -100.00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -9,725,122 | 0 | -100.00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -1,487,371 | 0 | -100.00 | ||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11,585,199 | 11,585,199 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 11,441,326 | 11,441,326 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 9,725,122 | 9,725,122 | |||||
| 2021-02-10 |
|
4 | SANA |
Sana Biotechnology, Inc.
Common Stock |
C - Conversion | 1,487,371 | 1,487,371 | |||||
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 46,429 | 4,125,461 | 1.14 | 15.00 | 696,435 | 61,881,915 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37,143 | 1,370,476 | 2.79 | 15.00 | 557,145 | 20,557,140 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 37,143 | 1,370,476 | 2.79 | 15.00 | 557,145 | 20,557,140 | |
| 2021-02-04 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 9,285 | 791,529 | 1.19 | 15.00 | 139,275 | 11,872,935 | |
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,481,481 | 0 | -100.00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -370,370 | 0 | -100.00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -4,074,074 | 0 | -100.00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,444,444 | 0 | -100.00 | ||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 1,481,481 | 1,481,481 | |||||
| 2020-12-10 |
|
4 | SGTX |
Sigilon Therapeutics, Inc.
Common Stock |
C - Conversion | 8,888,888 | 8,888,888 | |||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -43,154 | 0 | -100.00 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1,481,481 | 2,962,963 | -33.33 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -1,186,310 | 3,258,134 | -26.69 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -966,234 | 0 | -100.00 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -642,180 | 1,283,282 | -33.35 | ||||
| 2020-11-25 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
J - Other | -3,587,820 | 4,434,600 | -44.72 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3,333,333 | 0 | -100.00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -2,666,666 | 0 | -100.00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,336,293 | 0 | -100.00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -8,333,333 | 0 | -100.00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -7,500,000 | 0 | -100.00 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,851,801 | 2.78 | 16.00 | 800,000 | 29,628,816 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,851,801 | 2.78 | 16.00 | 800,000 | 29,628,816 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1,801,801 | 1,801,801 | |||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
P - Purchase | 50,000 | 1,491,441 | 3.47 | 16.00 | 800,000 | 23,863,056 | |
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 1,441,441 | 1,441,441 | |||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 722,320 | 9,280,878 | 8.44 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4,504,504 | 8,558,558 | 111.11 | ||||
| 2020-10-29 |
|
4 | FHTX |
Foghorn Therapeutics Inc.
Common Stock |
C - Conversion | 4,054,054 | 4,054,054 | |||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660,048 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series C Preferred Stock |
C - Conversion | -660,048 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,416,666 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,416,666 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4,250,000 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Series A Preferred Stock |
C - Conversion | -4,250,000 | 0 | -100.00 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
P - Purchase | 165,000 | 1,143,177 | 16.87 | 15.00 | 2,475,000 | 17,147,655 | |
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95,861 | 978,177 | 10.86 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 95,861 | 978,177 | 10.86 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338,630 | 882,316 | 62.28 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 338,630 | 882,316 | 62.28 | ||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543,686 | 543,686 | |||||
| 2020-10-20 |
|
4 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
C - Conversion | 543,686 | 543,686 | |||||
| 2020-10-13 | 3 | CDAK |
Codiak BioSciences, Inc.
Common Stock |
485,949 | ||||||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2,053,049 | 0 | -100.00 | ||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,449,190 | 4,971,576 | -22.57 | ||||
| 2020-08-19 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -7,550,810 | 14,435,589 | -34.34 | ||||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,666,667 | 4,079,032 | 69.09 | 3.75 | 6,250,001 | 15,296,370 | |
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,333,333 | 1,333,333 | 3.75 | 4,999,999 | 4,999,999 | ||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1,333,333 | 1,333,333 | 3.75 | 4,999,999 | 4,999,999 | ||
| 2020-07-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 782,244 | 74.25 | 3.75 | 1,249,999 | 2,933,415 | |
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,666 | 666,666 | 7.50 | 4,999,995 | 4,999,995 | ||
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,667 | 2,910,972 | 29.70 | 7.50 | 5,000,002 | 21,832,290 | |
| 2020-06-08 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 666,667 | 2,910,972 | 29.70 | 7.50 | 5,000,002 | 21,832,290 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -10,746 | 6,420,766 | -0.17 | 70.18 | -754,113 | 450,584,959 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -69,254 | 6,431,512 | -1.07 | 69.45 | -4,809,448 | 446,645,998 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -56,406 | 21,986,399 | -0.26 | 70.18 | -3,958,353 | 1,542,919,735 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -363,594 | 22,042,805 | -1.62 | 69.45 | -25,250,331 | 1,530,795,657 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -367 | 6,500,766 | -0.01 | 72.44 | -26,584 | 470,886,236 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -2,551 | 6,501,133 | -0.04 | 71.51 | -182,433 | 464,924,626 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -3,900 | 6,503,684 | -0.06 | 70.46 | -274,780 | 458,226,161 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -7,443 | 6,507,584 | -0.11 | 68.81 | -512,185 | 447,814,838 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -23,199 | 6,515,027 | -0.35 | 67.15 | -1,557,822 | 437,486,669 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -42,540 | 6,538,226 | -0.65 | 65.77 | -2,797,690 | 429,993,625 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -1,933 | 22,406,399 | -0.01 | 72.44 | -140,017 | 1,623,009,752 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -13,408 | 22,408,332 | -0.06 | 71.51 | -958,861 | 1,602,511,695 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -20,492 | 22,421,740 | -0.09 | 70.46 | -1,443,793 | 1,579,755,082 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -39,082 | 22,442,232 | -0.17 | 68.81 | -2,689,404 | 1,544,348,730 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -121,771 | 22,481,314 | -0.54 | 67.15 | -8,176,971 | 1,509,629,228 | |
| 2020-05-26 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -223,314 | 22,603,085 | -0.98 | 65.77 | -14,686,491 | 1,486,516,748 | |
| 2020-05-26 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,900,000 | 2,886,023 | 192.69 | 4.75 | 9,025,000 | 13,708,609 | |
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 380,000 | 1,056,752 | 56.15 | 4.75 | 1,805,000 | 5,019,572 | |
| 2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1,520,000 | 4,808,780 | 46.22 | 4.75 | 7,220,000 | 22,841,705 | |
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -2,281,179 | 0 | -100.00 | ||||
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,610,000 | 6,580,766 | -19.66 | ||||
| 2020-05-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -8,390,000 | 22,826,399 | -26.88 | ||||
| 2020-04-30 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 18,270 | 18,270 | |||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -38,366 | 8,190,766 | -0.47 | 18.65 | -715,710 | 152,797,102 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -199,935 | 31,216,399 | -0.64 | 18.65 | -3,729,747 | 582,335,680 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -4,092 | 8,229,132 | -0.05 | 18.96 | -77,579 | 156,012,822 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -21,325 | 31,416,334 | -0.07 | 18.96 | -404,292 | 595,609,710 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -27,714 | 8,233,224 | -0.34 | 18.99 | -526,408 | 156,384,327 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
S - Sale | -144,423 | 31,437,659 | -0.46 | 18.99 | -2,743,199 | 597,133,183 | |
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,735,720 | 0 | -100.00 | ||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -1,207,658 | 8,260,938 | -12.75 | ||||
| 2019-12-11 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
J - Other | -6,292,342 | 31,582,082 | -16.61 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -248,379 | 0 | -100.00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -61,537 | 0 | -100.00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1,061,102 | 0 | -100.00 | ||||
| 2019-10-31 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -1,469,173 | 0 | -100.00 | ||||
| 2019-06-28 |
|
4 | MRNA |
Moderna, Inc.
Stock Option (Right to Buy) |
A - Award | 54,660 | 54,660 | |||||
| 2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4,444,444 | 4,444,444 | 2.25 | 9,999,999 | 9,999,999 | ||
| 2019-06-20 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
P - Purchase | 4,444,444 | 4,444,444 | 2.25 | 9,999,999 | 9,999,999 | ||
| 2019-06-14 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
| 2019-06-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 15,690 | 15,690 | |||||
| 2019-05-28 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -895,255 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -89,525 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series E Preferred Stock |
C - Conversion | -358,102 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -151,643 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -617,914 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series C Preferred Stock |
C - Conversion | -222,506 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -1,005,413 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -928,074 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series B Preferred Stock |
C - Conversion | -386,697 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -4,153,847 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Series A Preferred Stock |
C - Conversion | -1,384,615 | 0 | -100.00 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 500,000 | 986,023 | 102.88 | 20.00 | 10,000,000 | 19,720,460 | |
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 486,023 | 486,023 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 48,602 | 676,752 | 7.74 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 194,409 | 3,288,780 | 6.28 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 82,324 | 628,150 | 15.08 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 335,457 | 3,094,371 | 12.16 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 120,795 | 1,761,029 | 7.36 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 545,826 | 545,826 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 503,840 | 2,758,914 | 22.34 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 209,933 | 1,640,234 | 14.68 | ||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 2,255,074 | 2,255,074 | |||||
| 2019-05-15 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
C - Conversion | 751,691 | 1,430,301 | 110.77 | ||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
3,393,050 | ||||||||
| 2019-05-08 | 3 | AXLA |
Axcella Health Inc.
Common Stock |
4,750,270 | ||||||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -1,682,665 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -450,958 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -600,000 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -1,257,465 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -992,110 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1,400,000 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -2,000,000 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 792,366 | 1,061,102 | 294.85 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
C - Conversion | 1,254,888 | 1,469,173 | 585.62 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 268,736 | 268,736 | |||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -940,579 | 0 | -100.00 | ||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | 214,285 | 214,285 | |||||
| 2019-05-06 |
|
4 | TMDX |
TransMedics Group, Inc.
Common Stock |
J - Other | -750,000 | 0 | -100.00 | ||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
697,306 | ||||||||
| 2019-05-01 | 3 | TMDX |
TransMedics Group, Inc.
Common Stock |
751,757 | ||||||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1,251,251 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -1,251,251 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -2,570,694 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -1,928,021 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -642,674 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,278,720 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -852,480 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -9,275,111 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -3,091,704 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 2,244,305 | 17.44 | 15.00 | 4,999,995 | 33,664,575 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 333,333 | 2,244,305 | 17.44 | 15.00 | 4,999,995 | 33,664,575 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
P - Purchase | 266,667 | 2,560,096 | 11.63 | 15.00 | 4,000,005 | 38,401,440 | |
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625,625 | 1,910,972 | 48.67 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 625,625 | 1,910,972 | 48.67 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1,285,347 | 1,285,347 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 964,010 | 5,601,565 | 20.79 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 321,337 | 2,293,429 | 16.29 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 639,360 | 639,360 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 426,240 | 1,972,092 | 27.57 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 4,637,555 | 4,637,555 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 1,545,852 | 1,545,852 | |||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -562,407 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -347,173 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -1,331,816 | 0 | -100.00 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 281,203 | 947,111 | 42.23 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 173,586 | 216,451 | 404.96 | ||||
| 2019-03-06 |
|
4 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
C - Conversion | 665,908 | 665,908 | |||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
1,778,594 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
3,385,728 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2019-02-27 | 3 | KLDO |
Kaleido Biosciences, Inc.
Common Stock |
5,000,000 | ||||||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -21,496 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series D Preferred Stock |
C - Conversion | -85,989 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -1,428,432 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series C Preferred Stock |
C - Conversion | -5,713,739 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -6,195,632 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series B Preferred Stock |
C - Conversion | -24,782,551 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -1,823,036 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Series A Preferred Stock |
C - Conversion | -7,292,145 | 0 | -100.00 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 21,496 | 9,468,596 | 0.23 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 85,989 | 37,874,424 | 0.23 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1,428,432 | 9,447,100 | 17.81 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 5,713,739 | 37,788,435 | 17.81 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 6,195,632 | 8,018,668 | 339.85 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 24,782,551 | 32,074,696 | 339.85 | ||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 1,823,036 | 1,823,036 | |||||
| 2018-12-13 |
|
4 | MRNA |
Moderna, Inc.
Common Stock |
C - Conversion | 7,292,145 | 7,292,145 | |||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
22,924,794 | ||||||||
| 2018-12-07 | 3 | MRNA |
Moderna, Inc.
Common Stock |
11,468,283 | ||||||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -781,860 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195,466 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -195,466 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1,781,843 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593,948 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -593,948 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -5,000,000 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3,830,402 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -15,323,593 | 0 | -100.00 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 781,860 | 2,563,703 | 43.88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195,466 | 5,789,414 | 3.49 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 195,466 | 5,789,414 | 3.49 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 1,781,843 | 1,781,843 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593,948 | 5,593,948 | 11.88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 593,948 | 5,593,948 | 11.88 | ||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5,000,000 | 5,000,000 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 5,000,000 | 5,000,000 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 3,830,402 | 3,830,402 | |||||
| 2018-07-23 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
C - Conversion | 15,323,593 | 15,323,593 | |||||
| 2018-07-18 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
10,000,000 | ||||||||
| 2018-06-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -4,643,963 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -18,611,110 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-3 Preferred Stock |
C - Conversion | -8,333,000 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-2 Preferred Stock |
C - Conversion | -5,416,667 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A-1 Preferred Stock |
C - Conversion | -10,102,055 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -12,536,945 | 0 | -100.00 | ||||
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 281,250 | 18,233,403 | 1.57 | 16.00 | 4,500,000 | 291,734,448 | |
| 2018-05-15 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
C - Conversion | 14,622,143 | 17,952,153 | 439.10 | ||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-05-08 | 3 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
6,660,018 | ||||||||
| 2018-02-13 |
|
5 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
G - Gift | -24,527 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series C Preferred Stock |
C - Conversion | -352,800 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series B Preferred Stock |
C - Conversion | -1,533,214 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-2 Preferred Stock |
C - Conversion | -3,360,000 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Series A-1 Preferred Stock |
C - Conversion | -1,280,000 | 0 | -100.00 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 109,770 | 2,030,495 | 5.72 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 477,042 | 1,920,725 | 33.04 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 1,045,426 | 1,443,683 | 262.50 | ||||
| 2017-12-13 |
|
4 | QTRX |
Quanterix Corp
Common Stock |
C - Conversion | 398,257 | 398,257 | |||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series B-1 Preferred Stock |
C - Conversion | -156,250 | 0 | -100.00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-2 Preferred Stock |
C - Conversion | -125,000 | 0 | -100.00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Series A-1 Preferred Stock |
C - Conversion | -8,324,999 | 0 | -100.00 | ||||
| 2017-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
C - Conversion | 8,606,249 | 8,918,749 | 2,754.00 | ||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
| 2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
625,000 | ||||||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -54,293 | 0 | -100.00 | ||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -306,222 | 612,442 | -33.33 | ||||
| 2017-08-21 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
J - Other | -1,295,997 | 2,378,663 | -35.27 | ||||
| 2017-06-21 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10,293 | 106,787 | -8.79 | 3.10 | -31,908 | 331,040 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -41,178 | 426,885 | -8.80 | 3.10 | -127,652 | 1,323,344 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3,118 | 117,080 | -2.59 | 3.16 | -9,853 | 369,973 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12,482 | 468,063 | -2.60 | 3.16 | -39,443 | 1,479,079 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -47,090 | 120,198 | -28.15 | 3.17 | -149,275 | 381,028 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -188,367 | 480,545 | -28.16 | 3.17 | -597,123 | 1,523,328 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -28,163 | 167,288 | -14.41 | 3.18 | -89,558 | 531,976 | |
| 2016-09-26 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -112,731 | 668,912 | -14.42 | 3.18 | -358,485 | 2,127,140 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -64,509 | 195,451 | -24.81 | 3.75 | -241,909 | 732,941 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -258,214 | 781,643 | -24.83 | 3.75 | -968,302 | 2,931,161 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -10,778 | 259,960 | -3.98 | 3.39 | -36,537 | 881,264 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -43,139 | 1,039,857 | -3.98 | 3.39 | -146,241 | 3,525,115 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -1,939 | 270,738 | -0.71 | 3.31 | -6,418 | 896,143 | |
| 2016-09-21 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -7,761 | 1,082,996 | -0.71 | 3.31 | -25,689 | 3,584,717 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -536 | 272,677 | -0.20 | 4.16 | -2,230 | 1,134,336 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -2,145 | 1,090,757 | -0.20 | 4.16 | -8,923 | 4,537,549 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8,802 | 273,213 | -3.12 | 4.18 | -36,792 | 1,142,030 | |
| 2016-09-16 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -35,209 | 1,092,902 | -3.12 | 4.18 | -147,174 | 4,568,330 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -8,145 | 282,015 | -2.81 | 4.51 | -36,734 | 1,271,888 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -32,597 | 1,128,111 | -2.81 | 4.51 | -147,012 | 5,087,781 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -52,985 | 1,833,802 | -2.81 | 4.51 | -238,962 | 8,270,447 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -3,108 | 290,160 | -1.06 | 4.63 | -14,390 | 1,343,441 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -12,441 | 1,160,708 | -1.06 | 4.63 | -57,602 | 5,374,078 | |
| 2016-09-08 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
S - Sale | -20,221 | 1,886,787 | -1.06 | 4.63 | -93,623 | 8,735,824 | |
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -50,271 | 0 | -100.00 | ||||
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -300,000 | 691,060 | -30.27 | ||||
| 2016-08-15 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
J - Other | -1,200,000 | 2,764,256 | -30.27 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -444,995 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1,779,981 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -1,500,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-3 Preferred Stock |
C - Conversion | -6,000,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1,000,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4,000,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -200,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Series A-1 Preferred Stock |
C - Conversion | -800,000 | 0 | -100.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 80,000 | 918,664 | 9.54 | 12.50 | 1,000,000 | 11,483,300 | |
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 320,000 | 3,674,660 | 9.54 | 12.50 | 4,000,000 | 45,933,250 | |
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 118,665 | 838,664 | 16.48 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 474,661 | 3,354,660 | 16.48 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 400,000 | 719,999 | 125.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,600,000 | 2,879,999 | 125.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 266,666 | 319,999 | 500.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1,066,666 | 1,279,999 | 500.00 | ||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 53,333 | 53,333 | |||||
| 2016-07-07 |
|
4 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 213,333 | 213,333 | |||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -125,008 | 0 | -100.00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -241,718 | 0 | -100.00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -235,042 | 0 | -100.00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series B Convertible Preferred Stock |
C - Conversion | -631,458 | 0 | -100.00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series A Convertible Preferred Stock |
C - Conversion | -318,752 | 0 | -100.00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 193,777 | 1,651,862 | 13.29 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 241,718 | 1,458,085 | 19.87 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 235,042 | 1,216,367 | 23.95 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 631,458 | 981,325 | 180.49 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 318,752 | 349,867 | 1,024.43 | ||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-29 | 3 | SYRS |
Syros Pharmaceuticals, Inc.
Common Stock |
426,664 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
62,230 | ||||||||
| 2016-06-17 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -33,514 | 0 | -100.00 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 7 | 33,514 | 0.02 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | 33,507 | 33,514 | 478,671.43 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -200,000 | 1,925,462 | -9.41 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
J - Other | -800,000 | 8,022,420 | -9.07 | ||||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -599,297 | 0 | -100.00 | 27.60 | -16,540,597 | ||
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -80,141 | 1,925,462 | -4.00 | 27.60 | -2,211,892 | 53,142,751 | |
| 2016-05-27 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
S - Sale | -320,562 | 2,734,994 | -10.49 | 27.60 | -8,847,511 | 75,485,834 | |
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -199,999 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1,051,060 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -1,325,708 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series B Preferred Stock |
C - Conversion | -800,001 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4,204,240 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Series A-1 Preferred Stock |
C - Conversion | -5,302,834 | 0 | -100.00 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 76,922 | 991,060 | 8.41 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 404,253 | 914,138 | 79.28 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 509,885 | 509,885 | |||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 307,692 | 3,964,256 | 8.41 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 1,617,015 | 3,656,564 | 79.28 | ||||
| 2016-02-09 |
|
4 | EDIT |
Editas Medicine, Inc.
Common Stock |
C - Conversion | 2,039,549 | 2,039,549 | |||||
| 2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -2,508 | 0 | -100.00 | 0.56 | -1,404 | ||
| 2015-12-11 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -43,930 | 0 | -100.00 | 0.56 | -24,601 | ||
| 2015-11-20 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 5,000 | 5,000 | |||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -508 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -254 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -3,256 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 58,232 | -0.05 | 2.27 | -73 | 132,187 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 508 | 58,264 | 0.88 | 0.14 | 71 | 8,157 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -16 | 57,756 | -0.03 | 2.27 | -36 | 131,106 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 254 | 57,772 | 0.44 | 0.14 | 36 | 8,088 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -206 | 56,804 | -0.36 | 2.27 | -468 | 128,945 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 3,256 | 57,010 | 6.06 | 0.14 | 456 | 7,981 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -8,410 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -4,205 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -53,857 | 0 | -100.00 | ||||
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -530 | 786,970 | -0.07 | 2.27 | -1,203 | 1,786,422 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 8,410 | 787,500 | 1.08 | 0.14 | 1,177 | 110,250 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -265 | 779,090 | -0.03 | 2.27 | -602 | 1,768,534 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 4,205 | 779,355 | 0.54 | 0.14 | 589 | 109,110 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -3,390 | 763,330 | -0.44 | 2.27 | -7,695 | 1,732,759 | |
| 2015-07-29 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 53,857 | 766,720 | 7.56 | 0.14 | 7,540 | 107,341 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 397,072 | 497,729 | 394.48 | 1.70 | 675,142 | 846,289 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 100,657 | 100,657 | |||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 53,465 | 67,018 | 394.49 | 1.70 | 90,907 | 113,951 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 13,553 | 13,553 | |||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
C - Conversion | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Secured Convertible Promissory Note |
J - Other | |||||||
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
P - Purchase | 725,725 | 909,696 | 394.48 | 1.70 | 1,233,950 | 1,546,756 | |
| 2015-07-16 |
|
4 | BGMD |
BG Medicine, Inc.
Series A Preferred Stock |
C - Conversion | 183,971 | 183,971 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -454,546 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,818,181 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -224,719 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -898,877 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -599,297 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,526,338 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6,105,362 | 0 | -100.00 | ||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 599,297 | 599,297 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 2,205,603 | 2,205,603 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Common Stock, $0.001 par value |
C - Conversion | 8,822,420 | 8,822,420 | |||||
| 2015-06-29 |
|
4 | MCRB |
Seres Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 15,000 | 15,000 | |||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2015-06-25 | 3 | MCRB |
Seres Therapeutics, Inc.
Common Stock |
6,111,112 | ||||||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 10,029 | 10,029 | |||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 164,528 | 175,718 | 1,470.31 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -2,484,192 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -17,080 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2,484,192 | -0.02 | 0.46 | -283 | 1,142,728 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 2,484,192 | -0.02 | 0.46 | -283 | 1,142,728 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 17,080 | 2,484,808 | 0.69 | 0.02 | 342 | 49,696 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -616 | 7,298,474 | -0.01 | 0.46 | -283 | 3,357,298 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98,570 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,729 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -850 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -499 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,570 | -0.06 | 0.46 | -29 | 45,342 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,729 | 98,633 | 1.78 | 0.02 | 35 | 1,973 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -32 | 93,572 | -0.03 | 0.46 | -15 | 43,043 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 850 | 93,604 | 0.92 | 0.02 | 17 | 1,872 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -39 | 92,754 | -0.04 | 0.46 | -18 | 42,667 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 499 | 92,793 | 0.54 | 0.04 | 20 | 3,712 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -98,352 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -1,724 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -847 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -464 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -63 | 98,352 | -0.06 | 0.46 | -29 | 45,242 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 1,724 | 98,415 | 1.78 | 0.02 | 34 | 1,968 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -31 | 93,369 | -0.03 | 0.46 | -14 | 42,950 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 847 | 93,400 | 0.92 | 0.02 | 17 | 1,868 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -37 | 92,553 | -0.04 | 0.46 | -17 | 42,574 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 464 | 92,590 | 0.50 | 0.04 | 19 | 3,704 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | 11,190 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -703,655 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,183 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -5,988 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -12,021 | 0 | -100.00 | ||||
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -440 | 703,655 | -0.06 | 0.46 | -202 | 323,681 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,183 | 704,095 | 1.76 | 0.02 | 244 | 14,082 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -216 | 668,426 | -0.03 | 0.46 | -99 | 307,476 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 5,988 | 668,642 | 0.90 | 0.02 | 120 | 13,373 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -927 | 662,654 | -0.14 | 0.46 | -426 | 304,821 | |
| 2014-12-05 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 12,021 | 663,581 | 1.84 | 0.04 | 481 | 26,543 | |
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -631,133 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -629,851 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -819,493 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,053,201 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -774,527 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -128,567 | 0 | -100.00 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 741,755 | 2,374,571 | 45.43 | ||||
| 2014-08-14 |
|
4 | TTOO |
T2 Biosystems, Inc.
Common Stock |
C - Conversion | 1,632,816 | 1,632,816 | |||||
| 2014-06-25 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
J - Other | -1,930,369 | 1,930,369 | -50.00 | ||||
| 2014-06-05 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
| 2014-03-24 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Stock Option |
A - Award | 16,143 | 16,143 | |||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series C Convertible Preferred Stock |
C - Conversion | -525,500 | 0 | -100.00 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock |
C - Conversion | -3,000,000 | 0 | -100.00 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 93,008 | 656,490 | 16.51 | ||||
| 2014-02-19 |
|
4 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 530,974 | 563,482 | 1,633.36 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -420,053 | 0 | -100.00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1,680,213 | 0 | -100.00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1,050,000 | 0 | -100.00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -4,200,000 | 0 | -100.00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -9,000,000 | 0 | -100.00 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 32,912 | 293,268 | 12.64 | 10.00 | 329,120 | 2,932,680 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 131,722 | 1,173,149 | 12.65 | 10.00 | 1,317,220 | 11,731,490 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
P - Purchase | 214,095 | 1,907,008 | 12.65 | 10.00 | 2,140,950 | 19,070,080 | |
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 231,504 | 260,356 | 802.38 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 926,017 | 1,041,427 | 802.37 | ||||
| 2014-02-13 |
|
4 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1,417,323 | 1,692,913 | 514.29 | ||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
| 2014-02-12 | 3 | CNCE |
CONCERT PHARMACEUTICALS, INC.
Common Stock |
65,016 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
695,442 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
535,262 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
448,704 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
275,590 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
115,410 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
Common Stock |
28,852 | ||||||||
| 2014-02-05 | 3 | EBIO |
Eleven Biotherapeutics, Inc.
No securities are beneficially owned |
0 | ||||||||
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -20,300 | 1,693,551 | -1.18 | 24.09 | -489,027 | 40,797,644 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -904 | 1,713,851 | -0.05 | 25.10 | -22,690 | 43,017,660 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -54,000 | 1,714,755 | -3.05 | 24.20 | -1,306,800 | 41,497,071 | |
| 2013-11-18 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
S - Sale | -155,583 | 1,768,755 | -8.09 | 25.03 | -3,894,242 | 44,271,938 | |
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series D Preferred Stock |
C - Conversion | -407,060 | 0 | -100.00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C-1 Preferred Stock |
C - Conversion | -333,288 | 0 | -100.00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series C Preferred Stock |
C - Conversion | -416,667 | 0 | -100.00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series B Preferred Stock |
C - Conversion | -1,900,000 | 0 | -100.00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Series A Preferred Stock |
C - Conversion | -984,640 | 0 | -100.00 | ||||
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
P - Purchase | 20,000 | 1,562,616 | 1.30 | 15.00 | 300,000 | 23,439,240 | |
| 2013-09-27 |
|
4 | BIND |
BIND Therapeutics, Inc
Common Stock |
C - Conversion | 1,542,616 | 1,542,616 | |||||
| 2013-09-18 | 3 | XLRN |
ACCELERON PHARMA INC
Common Stock |
4,867 | ||||||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series C-2 Convertible Preferred Stock |
C - Conversion | -617,031 | 0 | -100.00 | ||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -10,000,000 | 0 | -100.00 | ||||
| 2013-07-31 |
|
4 | AGIO |
AGIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 3,860,738 | 3,860,738 | |||||
| 2013-06-14 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series B Preferred Stock |
C - Conversion | -4,131,552 | 0 | -100.00 | ||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Series A Preferred Stock |
C - Conversion | -8,640,289 | 0 | -100.00 | ||||
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
P - Purchase | 107,142 | 1,924,339 | 5.90 | 14.00 | 1,499,988 | 26,940,746 | |
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 550,873 | 1,817,197 | 43.50 | 7.73 | 4,258,248 | 14,046,933 | |
| 2013-05-14 |
|
4 | RCPT |
Receptos, Inc.
Common Stock |
C - Conversion | 1,152,039 | 1,266,324 | 1,008.04 | 5.25 | 6,048,205 | 6,648,201 | |
| 2013-05-08 | 3 | RCPT |
Receptos, Inc.
Common Stock |
114,285 | ||||||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -19,544,924 | 0 | -100.00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series C Convertible Participating Preferred Stock |
C - Conversion | -9,626,604 | 0 | -100.00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series B Convertible Participating Preferred Stock |
C - Conversion | -11,422,045 | 0 | -100.00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-2 Convertible Participating Preferred Stock |
C - Conversion | -2,726,088 | 0 | -100.00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Series A-1 Convertible Participating Preferred Stock |
C - Conversion | -2,090,000 | 0 | -100.00 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 491,824 | 1,165,786 | 72.98 | 7.00 | 3,442,768 | 8,160,502 | |
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 673,962 | 673,962 | |||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 331,953 | 891,887 | 59.28 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 393,863 | 559,934 | 237.17 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 94,003 | 166,071 | 130.44 | ||||
| 2013-03-27 |
|
4 | TTPH |
TETRAPHASE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 72,068 | 72,068 | |||||
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 1,050,000 | 1,764,286 | 147.00 | 2.00 | 2,100,000 | 3,528,572 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 500,000 | 2,851,447 | 21.26 | 2.00 | 1,000,000 | 5,702,894 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 75,000 | 215,013 | 53.57 | 2.00 | 150,000 | 430,026 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 125,000 | 651,560 | 23.74 | 2.00 | 250,000 | 1,303,120 | |
| 2013-02-01 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
P - Purchase | 250,000 | 2,434,800 | 11.44 | 2.00 | 500,000 | 4,869,600 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -298,137 | 0 | -100.00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -6,422 | 0 | -100.00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,353 | 0 | -100.00 | ||||
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298,137 | -0.01 | 5.83 | -134 | 1,738,139 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 298,137 | -0.01 | 5.83 | -134 | 1,738,139 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 298,160 | 2.20 | 0.02 | 128 | 5,963 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 298,160 | 2.20 | 0.02 | 128 | 5,963 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -23 | 285,339 | -0.01 | 5.83 | -134 | 1,663,526 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 6,422 | 285,362 | 2.30 | 0.02 | 128 | 5,707 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -13 | 278,940 | 0.00 | 5.83 | -76 | 1,626,220 | |
| 2012-08-22 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,353 | 278,953 | 0.85 | 0.03 | 71 | 8,369 | |
| 2012-06-13 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 | |||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
J - Other | -130,867 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -7,001 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,580 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | -2,497 | 0 | -100.00 | ||||
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -36 | 130,867 | -0.03 | 3.95 | -142 | 516,925 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 7,001 | 130,903 | 5.65 | 0.02 | 140 | 2,618 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -14 | 109,972 | -0.01 | 3.95 | -55 | 434,389 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,580 | 109,986 | 2.40 | 0.02 | 52 | 2,200 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
S - Sale | -19 | 107,406 | -0.02 | 3.95 | -75 | 424,254 | |
| 2012-05-23 |
|
4 | BGMD |
BG Medicine, Inc.
Common Stock |
X - Other | 2,497 | 107,425 | 2.38 | 0.03 | 75 | 3,223 | |
| 2012-02-29 |
|
4 | BGMD |
BG Medicine, Inc.
Stock Option (right to buy) |
A - Award | 4,205 | 4,205 |
